The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...

Margin expansion at Express Scripts, Caremark and Optum Rx increased by $336 million between 2017 and 2021, officials say.

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...

In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...